rivastigmine

rivastigmine
Bioavailability	~36%
T_max	1.0–1.4 hours
Protein binding	~40%
C_max (steady state)	~21.6 ng/mL (6 mg BID)
Volume of distribution	~1.8–2.7 L/kg
Adverse Effect	Oral (12 mg/day)
Nausea	47%
Vomiting	31%
Diarrhea	19%
Anorexia	17%
Dizziness	13%
Weight loss	3–7%
Headache	13%
Feature	Rivastigmine
AChE inhibition	Yes (pseudo-irreversible)
BuChE inhibition	Yes
Nicotinic receptor modulation	No
CYP metabolism	No (esterase hydrolysis)
FDA approval: AD	Yes
FDA approval: PDD	Yes
Transdermal patch	Yes
Drug interaction risk	Low

Introduction

Rivastigmine is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Rivastigmine (brand name Exelon) is a carbamate-derived, pseudo-irreversible cholinesterase inhibitor used for the symptomatic ^{1Citation2002 · PMID 12162759Open reference} treatment of mild-to-moderate dementia in alzheimers (AD) and parkinsons dementia (PDD). Uniquely among the approved ^{2Citation2000 · PMID 10641971Open reference} cholinesterase-inhibitors, rivastigmine inhibits both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), and is available in a ^{3Citation2000Open reference} transdermal patch formulation that offers improved tolerability over oral dosing ^{4Citation1998 · Int J Geriatr Psychopharmacol 5Citation2004 · PMID 15590953Open reference 1Citation2002 · PMID 12162759Open reference 6'A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer''s Disease—rivastigmine patch versus capsule. *Int J Geriatr Psychiatry*. 2007;22(5):456-467.2007 · PMID 17646619Open reference} . It ^{7Rivastigmine transdermal patch skin tolerability and use in clinical practice2010 · Alzheimers Dement (N Y]} remains a first-line symptomatic therapy for dementia and is the only cholinesterase inhibitor with FDA ^{8Citation2002 · PMID 11888271Open reference} approval for PDD. ^{9Citation2013 · PMID 24179466Open reference}

History and Development

Rivastigmine was originally synthesized by Marta Weinstock-Rosin at the Department of Pharmacology, Hebrew University of Jerusalem. The compound was licensed to Sandoz (later Novartis) through Yissum, the technology transfer company of Hebrew University. The molecule was selected for development based on its high affinity for brain AChE relative to peripheral forms of the enzyme, a property that suggested favorable CNS selectivity ^{2Citation2000 · PMID 10641971Open reference}0. ^{2Citation2000 · PMID 10641971Open reference}1

Key regulatory milestones include: ^{2Citation2000 · PMID 10641971Open reference}2

• 2000: FDA approval of oral rivastigmine (Exelon capsules and oral solution) for mild-to-moderate alzheimers ^{2Citation2000 · PMID 10641971Open reference}3

• 2006: FDA approval for parkinsons dementia, following the EXPRESS trial ^{2Citation2000 · PMID 10641971Open reference}4

• 2007: FDA approval of the transdermal patch (Exelon Patch), following the IDEAL trial ^{2Citation2000 · PMID 10641971Open reference}5

• 2013: Expanded indication for the 13.3 mg/24h patch to treat severe alzheimers ^{2Citation2000 · PMID 10641971Open reference}6

Generic formulations became available following patent expiration, and rivastigmine is now widely available worldwide. ^{2Citation2000 · PMID 10641971Open reference}7

Chemistry and Pharmacology

Chemical Structure

Rivastigmine is chemically designated as (S)-N-ethyl-N-methyl-3-1-(dimethylamino)ethyl-phenyl carbamate hydrogen-(2R,3R)-tartrate. Its ^{2Citation2000 · PMID 10641971Open reference}8 molecular formula is C₁₄H₂₂N₂O₂ (free base), with a molecular weight of 250.34 g/mol. The pharmacophore is its carbamate moiety, which ^{2Citation2000 · PMID 10641971Open reference}9 undergoes a covalent reaction with the active-site serine of cholinesterases, producing a carbamylated enzyme intermediate that is slow to ^{3Citation2000Open reference}0 regenerate ^{3Citation2000Open reference}1 ^{3Citation2000Open reference}2 ^{3Citation2000Open reference}3 ^{3Citation2000Open reference}4 . ^{3Citation2000Open reference}5

Mechanism of Action

Rivastigmine enhances cholinergic neurotransmission by inhibiting the enzymatic hydrolysis of acetylcholine (ACh). In alzheimers, progressive loss of cholinergic neurons in the nucleus-basalis-of-meynert leads to reduced ACh] levels in the cortex and hippocampus, contributing to cognitive decline. Rivastigmine acts to restore ACh] availability in these regions ^{3Citation2000Open reference}6. ^{3Citation2000Open reference}7

The inhibition mechanism is distinct from other cholinesterase inhibitors: ^{3Citation2000Open reference}8

1. Pseudo-irreversible binding: Rivastigmine carbamylates the catalytic serine residue at the active site of AChE and BuChE. The resulting carbamylated enzyme is slow to regenerate (half-life of decarbamylation ~10 hours), producing sustained inhibition despite the drug’s short plasma half-life of ~1.5 hours ^{3Citation2000Open reference}9 ^{4Citation1998 · Int J Geriatr Psychopharmacol}0 ^{4Citation1998 · Int J Geriatr Psychopharmacol}1 . ^{4Citation1998 · Int J Geriatr Psychopharmacol}2

2. Dual AChE/BuChE inhibition: Unlike donepezil, which selectively inhibits AChE, rivastigmine inhibits both AChE and BuChE with comparable potency. At therapeutic doses (12 mg/day oral), brain AChE and BuChE are inhibited by approximately 61.7% and 61.8%, respectively ^{4Citation1998 · Int J Geriatr Psychopharmacol}3 ^{4Citation1998 · Int J Geriatr Psychopharmacol}4 ^{4Citation1998 · Int J Geriatr Psychopharmacol}5 . This dual inhibition is clinically relevant because BuChE activity increases progressively in AD brains as AChE-producing neurons degenerate, and BuChE may assume a greater role in ACh hydrolysis as disease advances ^{4Citation1998 · Int J Geriatr Psychopharmacol}6 ^{4Citation1998 · Int J Geriatr Psychopharmacol}7 . ^{4Citation1998 · Int J Geriatr Psychopharmacol}8

3. G1 isoform selectivity: Rivastigmine preferentially inhibits the G1 enzymatic form of AChE, which predominates in the AD brain, and is a more potent inhibitor of cortical and hippocampal AChE than of peripheral forms ^{4Citation1998 · Int J Geriatr Psychopharmacol}9.

CNS Selectivity

Rivastigmine demonstrates favorable brain-over-periphery selectivity. Studies show approximately 40% inhibition of central AChE compared to only 10% inhibition of peripheral BuChE at therapeutic doses, indicating that the drug preferentially targets the CNS cholinergic system ^{5Citation2004 · PMID 15590953Open reference}0. This selectivity may contribute to a somewhat lower incidence of peripheral cholinergic side effects relative to the degree of central AChE inhibition achieved.

Pharmacokinetics

Absorption and Distribution

The transdermal patch provides significantly smoother pharmacokinetic profiles, with lower peak-to-trough fluctuations. The C_max with the 9.5 mg/24h patch is approximately 60% lower than with equivalent oral doses, while maintaining comparable overall drug exposure (AUC) ^{5Citation2004 · PMID 15590953Open reference}1 ^{5Citation2004 · PMID 15590953Open reference}2 . Patch absorption is highest when applied to the upper back, chest, or upper arm; abdominal and thigh application results in 20–30% lower exposure ^{5Citation2004 · PMID 15590953Open reference}3.

Metabolism and Elimination

Rivastigmine is primarily metabolized by target-mediated hydrolysis at the cholinesterase active site, yielding the decarbamylated metabolite NAP226-90, which has minimal pharmacological activity. Critically, rivastigmine does not undergo significant hepatic metabolism via cytochrome P450 (CYP) enzymes, distinguishing it from donepezil (CYP2D6/3A4) and galantamine (CYP2D6/3A4) ^{5Citation2004 · PMID 15590953Open reference}4^{5Citation2004 · PMID 15590953Open reference}5.

• Half-life: ~1.5 hours (oral), though pharmacological effect extends to ~10 hours due to pseudo-irreversible binding

• Excretion: ~90% renal (as metabolites)

• Drug interactions: Minimal CYP-mediated interactions; no clinically significant interactions with digoxin, warfarin, diazepam, or fluoxetine demonstrated in healthy volunteer studies ^{5Citation2004 · PMID 15590953Open reference}6

• Special populations: No dose adjustment required for mild-to-moderate hepatic impairment; contraindicated in severe hepatic impairment

Clinical Efficacy

Alzheimer’s Disease

Multiple randomized controlled trials have demonstrated rivastigmine’s efficacy in mild-to-moderate alzheimers:

Pivotal Oral Trials: The B303 and B304 studies (Rösler et al., 1999; Corey-Bloom et al., 1998) enrolled over 1,400 patients and showed statistically significant improvements in cognition (ADAS-Cog) and global function (CIBIC-Plus) with rivastigmine 6–12 mg/day versus placebo over 26 weeks. Intent-to-treat analyses showed a mean treatment difference of 3–4 points on the ADAS-Cog ^{5Citation2004 · PMID 15590953Open reference}7 ^{5Citation2004 · PMID 15590953Open reference}8 .

IDEAL Trial (Investigation of transDermal Exelon in Alzheimer’s Disease): This Phase 3, 24-week, double-blind study randomized 1,195 patients with mild-to-moderate AD to the rivastigmine 10 cm^{5Citation2004 · PMID 15590953Open reference}9 patch (9.5 mg/24h), 20 cm^{1Citation2002 · PMID 12162759Open reference}0 patch (17.4 mg/24h), oral capsules (12 mg/day), or placebo. The 9.5 mg/24h patch demonstrated efficacy comparable to oral capsules on ADAS-Cog and ADCS-CGIC, with approximately two-thirds fewer reports of nausea (7.2% vs 23.1%) and vomiting (6.2% vs 17.0%). The 20 cm^{1Citation2002 · PMID 12162759Open reference}1 patch showed numerically superior cognitive scores with tolerability similar to oral capsules ^{1Citation2002 · PMID 12162759Open reference}2. Two-thirds of caregivers preferred the patch formulation.

ACTION Trial: The 48-week study compared the high-dose 13.3 mg/24h patch to the 9.5 mg/24h patch in patients with severe AD (MMSE 3–12). The higher-dose patch showed significant cognitive benefits on the Severe Impairment Battery (SIB), supporting its use in advanced disease ^{1Citation2002 · PMID 12162759Open reference}3 ^{1Citation2002 · PMID 12162759Open reference}4 .

Parkinson’s Disease Dementia

EXPRESS Trial (EXelon in Parkinson’s Disease dementia Study): This landmark 24-week, double-blind, placebo-controlled trial randomized 541 patients with PDD to rivastigmine 3–12 mg/day or placebo. Results demonstrated ^{1Citation2002 · PMID 12162759Open reference}5:

• Cognition: Mean improvement of 2.1 points on ADAS-Cog in the rivastigmine group vs. mean decline of 0.7 points with placebo (p < 0.001)

• Global function: Clinically meaningful improvement on ADCS-CGIC in 19.8% of rivastigmine patients vs. 14.5% with placebo; clinically meaningful worsening in 13.0% vs. 23.1%

• Executive function and attention: Significant benefits demonstrated in Parkinson’s-relevant cognitive domains ^{1Citation2002 · PMID 12162759Open reference}6

• Activities of daily living: Significant improvement on the ADCS-ADL scale

A 24-week open-label extension showed that long-term treatment was well tolerated and provided sustained cognitive benefits at 48 weeks ^{1Citation2002 · PMID 12162759Open reference}7.

The EXPRESS trial led to FDA approval of rivastigmine for PDD in 2006, making it the first and still the only cholinesterase inhibitor specifically approved for this indication.

Other Investigational Uses

Rivastigmine has been studied in several other conditions with cholinergic deficits:

• lewy-body-dementia: Open-label and small controlled studies suggest benefits for cognitive and behavioral symptoms, particularly visual hallucinations ^{1Citation2002 · PMID 12162759Open reference}8

• vascular-dementia: The VantagE trial showed modest cognitive benefits ^{1Citation2002 · PMID 12162759Open reference}9

• Post-operative delirium: Investigated for prevention in surgical populations, with mixed results

• Apathy in parkinsons: A randomized trial showed no significant benefit for apathy in non-demented PD patients ^{6'A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer''s Disease—rivastigmine patch versus capsule. *Int J Geriatr Psychiatry*. 2007;22(5):456-467.2007 · PMID 17646619Open reference}0

Formulations and Dosing

Oral Capsules

• Available doses: 1.5 mg, 3 mg, 4.5 mg, 6 mg

• Titration: Start 1.5 mg twice daily; increase by 1.5 mg/dose every 2 weeks

• Target dose: 6 mg twice daily (12 mg/day)

• Administration: Take with food to reduce GI side effects

Oral Solution

• 2 mg/mL solution for patients with swallowing difficulties

• Same dosing as capsules

Transdermal Patch (Preferred Formulation)

The transdermal patch is now considered the preferred formulation due to substantially better GI tolerability ^{6'A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer''s Disease—rivastigmine patch versus capsule. *Int J Geriatr Psychiatry*. 2007;22(5):456-467.2007 · PMID 17646619Open reference}1 ^{6'A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer''s Disease—rivastigmine patch versus capsule. *Int J Geriatr Psychiatry*. 2007;22(5):456-467.2007 · PMID 17646619Open reference}2 :

• Available doses: 4.6 mg/24h, 9.5 mg/24h, 13.3 mg/24h

• Titration: Start with 4.6 mg/24h; increase to 9.5 mg/24h after ≥4 weeks; may increase to 13.3 mg/24h for moderate-to-severe disease

• Application: Once daily to clean, dry, hairless skin on the upper back (preferred), upper arm, or chest

• Rotation: Change application site daily; do not reuse the same site for 14 days

Switching from Oral to Patch

Patients on oral rivastigmine <6 mg/day may switch to the 4.6 mg/24h patch; those on 6–12 mg/day may switch to the 9.5 mg/24h patch. The first patch should be applied the day after the last oral dose ^{6'A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer''s Disease—rivastigmine patch versus capsule. *Int J Geriatr Psychiatry*. 2007;22(5):456-467.2007 · PMID 17646619Open reference}3.

Safety and Adverse Effects

Common Adverse Effects

The transdermal patch demonstrates a markedly improved GI tolerability profile compared to oral capsules, with nausea and vomiting rates comparable to placebo ^{6'A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer''s Disease—rivastigmine patch versus capsule. *Int J Geriatr Psychiatry*. 2007;22(5):456-467.2007 · PMID 17646619Open reference}4.

Patch-Specific Effects

• Application site reactions: Erythema, pruritus, dermatitis (8–12% of patients)

• Mild skin irritation usually does not require discontinuation

• Site rotation minimizes skin reactions

Serious Adverse Effects and Warnings

• Bradycardia and heart block: Cholinomimetic effects may exacerbate sinus node disease or conduction abnormalities; use with caution in patients with cardiac disease

• GI hemorrhage: Monitor for occult bleeding, especially in patients with peptic ulcer risk factors

• Seizures: May lower seizure threshold through cholinergic activation

• Bronchospasm: Use with caution in asthma and COPD

• Urinary obstruction: Cholinergic stimulation may worsen obstructive uropathy

• Tremor exacerbation: Particularly relevant in PDD patients (10.2% vs 3.9% with placebo in EXPRESS) ^{6'A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer''s Disease—rivastigmine patch versus capsule. *Int J Geriatr Psychiatry*. 2007;22(5):456-467.2007 · PMID 17646619Open reference}5

Overdose and Application Errors

In 2015, the FDA issued a safety alert regarding rivastigmine patch application errors, including application of multiple patches simultaneously, which can cause overdose with severe nausea, vomiting, and potentially life-threatening cholinergic crisis ^{6'A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer''s Disease—rivastigmine patch versus capsule. *Int J Geriatr Psychiatry*. 2007;22(5):456-467.2007 · PMID 17646619Open reference}6.

Comparison with Other Cholinesterase Inhibitors

Rivastigmine’s lack of CYP metabolism makes it particularly suitable for elderly patients on multiple medications, where drug–drug interaction risk is a concern ^{6'A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer''s Disease—rivastigmine patch versus capsule. *Int J Geriatr Psychiatry*. 2007;22(5):456-467.2007 · PMID 17646619Open reference}7 ^{6'A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer''s Disease—rivastigmine patch versus capsule. *Int J Geriatr Psychiatry*. 2007;22(5):456-467.2007 · PMID 17646619Open reference}8 . Its dual AChE/BuChE inhibition may offer theoretical advantages in moderate-to-severe disease when BuChE becomes the predominant ACh-metabolizing enzyme ^{6'A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer''s Disease—rivastigmine patch versus capsule. *Int J Geriatr Psychiatry*. 2007;22(5):456-467.2007 · PMID 17646619Open reference}9.

Current Status and Future Directions

Rivastigmine remains a cornerstone of symptomatic treatment for alzheimers and parkinsons dementia. Current and emerging areas of investigation include:

• Combination therapy: Rivastigmine plus memantine is widely used clinically for moderate-to-severe AD, with evidence suggesting additive benefits on cognition and behavior ^{7Rivastigmine transdermal patch skin tolerability and use in clinical practice2010 · Alzheimers Dement (N Y]}0

• Novel delivery systems: Multi-day patches (twice-weekly application) are under investigation to improve adherence ^{7Rivastigmine transdermal patch skin tolerability and use in clinical practice2010 · Alzheimers Dement (N Y]}1

• Biomarker-guided treatment: Research into predicting cholinesterase inhibitor response using csf-biomarkers, cholinergic neuroimaging, and genetic markers (e.g., memantine

Background

The study of Rivastigmine has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Brain Atlas Resources

• Allen Human Brain Atlas: Rivastigmine expression search

• Allen Mouse Brain Atlas: Rivastigmine search

• Allen Cell Type Atlas: Transcriptomic cell type reference

• BrainSpan Developmental Transcriptome: Rivastigmine developmental expression

See Also

• [Alzheimer’s Disease[/Alzheimer’[s-disease[/Alzheimer’[s-disease[/Alzheimer’[s-disease[/Alzheimer’[s-disease[/Alzheimer’[s-disease[/Alzheimer’[s-disease[/Alzheimer’[s-disease[/Alzheimer’s-disease

• [Parkinson’s Disease[/Parkinson’[s-disease[/Parkinson’[s-disease[/Parkinson’[s-disease[/Parkinson’[s-disease[/Parkinson’[s-disease[/Parkinson’[s-disease[/Parkinson’[s-disease[/Parkinson’s-disease

• [Cholinesterase Inhibitor

• [Acetylcholinesterase

• [Donepezil

• [Galantamine

External Links

• PubMed Search: Rivastigmine

• Google Scholar Search: Rivastigmine